
Bristol acquires heart failure company Cardioxyl for up to $2.1bn
Executive Summary
Bristol-Myers Squibb Co. spent $300mm in up-front and near-term milestone payments for Cardioxyl Pharmaceuticals Inc., a private heart failure drug developer. Cardioxyl is also eligible for up to $1.775bn in development, regulatory, and sales milestones.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com